Introduction The use of breast fine needle aspiration biopsy (FNAB) for the detection of breast cancers varies greatly between clinicians, hospitals and countries. Core needle biopsy (CNB) is the gold-standard for histological diagnosis of breast cancers. At Manukau Breast Clinic (MBC), FNAB of palpable breast lesions are performed on lesions with low clinical suspicion of cancer. Patients are discharged if their results are C1 (inadequate) or C2 (benign). FNAB are resource intensive, uncomfortable and can cause unnecessary anxiety to patients. We aim to assess the utility of the procedure. Methods Retrospective review of all breast FNAB performed over 12 months at MBC. Data was collected using a database from the department of pathology. The indication for FNAB, patient factors, level of clinician performing the FNAB and cytology results were recorded from patient records. Analyses were performed using chi-square and student t-test. Results 80 patients at MBC underwent a FNAB from January 2021 to December 2021. The mean age was 50. 75 were female and 5 were male. 64 patients had C1, 11 had C2 and only 1 patient had C4 cytology (suspicious of malignancy). The C4 result later had a benign CNB. Registrars were significantly more likely to obtain a C1 result than Consultant Surgeons. Conclusion The majority of cytology results were C1 and most of these were performed by surgical registrars with a range of training. With only 1 of 80 lesions resulting in a C3+ result, balanced with the resource intensive process, discomfort, variability in results and patient anxiety, it is difficult to recommend the ongoing use of FNAB in breast lesions with low clinical suspicion of cancer.